A confirmatory study of masitinib in the treatment of Amyotrophic Lateral Sclerosis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Oct 2024 According to an AB science media release, company announces that European Medicines Agency (EMA) confirmed a negative opinion for conditional marketing authorization of masitinib in treatment of amyotrophic lateral sclerosis (ALS), this opinion supports design of this confirmatory study of masitinib in ALS, as the same dichotomization and the same cut-off have been pre-specified for the confirmatory study.
30 Sep 2019 According to an AB science media release, the company expects to initiate this study in Q1 2020.
30 May 2019 According to an AB science media release, the design, optimization and timelines from this trial will be presented in the company webcast on 4 June 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com